Replies to post #1987 on Fibrocell Science Inc (FCSC)

[DewDiligence]

I have to believe that with so many larger companies looking to expand their pipelines, an approved, new cell therapy with potentially huge markets for acne scarring down the road is the perfect candidate for a partnership/buyout.

Approval of laViv for acne scarring is the biotech equivalent of vaporware in the software business. It’s a hook being fed to unsophisticated investors so they will think that this formerly bankrupt company has a bright future.